Single-cell sequencing holds several technical advantages for understanding the complex profiles of the tumor immune microenvironment13,14 and has been used to uncover the determinants of anti-PD1 treatment response in melanoma, breast cancer, and clear cell renal cell carcinoma15–18. This evidence concerns the gene PDCD1 and neoplasm.